Anti-Fibrinolytic Drugs - Benelux

The Anti-Fibrinolytic Drugs market in Benelux is expected to witness a significant growth in revenue, projected to reach US$187.30m in 2024.
This market is anticipated to exhibit a steady annual growth rate (CAGR 2024-2029) of 4.41%, leading to a market volume of US$232.30m by 2029.
In comparison to other countries, United States is predicted to generate the highest revenue in this market, with an estimated value of US$9.86bn in 2024.
In the Benelux region, there has been a growing demand for anti-fibrinolytic drugs as the healthcare industry focuses on improving patient outcomes in surgeries and trauma cases.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The demand for Anti-Fibrinolytic Drugs in Benelux has been growing over the years, with an increasing number of patients being diagnosed with bleeding disorders.

Customer preferences: Patients in Benelux prefer Anti-Fibrinolytic Drugs due to their effectiveness in controlling bleeding. These drugs help in preventing the breakdown of blood clots, thereby reducing the risk of excessive bleeding. Patients also prefer these drugs as they have a lower risk of side effects compared to other medications.

Trends in the market: The Anti-Fibrinolytic Drugs market in Benelux is witnessing a trend towards the development of new and advanced drugs. Pharmaceutical companies are investing heavily in research and development to come up with more effective and safer drugs. The market is also witnessing an increasing demand for generic drugs due to their cost-effectiveness. The rising awareness among patients about the different treatment options available is also contributing to the growth of the market.

Local special circumstances: The healthcare system in Benelux is well-developed, with a high level of government spending on healthcare. The government provides universal health coverage to all citizens, which has resulted in increased access to healthcare services. This has led to an increase in the number of patients seeking treatment for bleeding disorders, thereby driving the demand for Anti-Fibrinolytic Drugs.

Underlying macroeconomic factors: The aging population in Benelux is one of the major factors driving the growth of the Anti-Fibrinolytic Drugs market. With an increase in age, the risk of bleeding disorders such as hemophilia and von Willebrand disease also increases. The growing prevalence of these disorders has resulted in an increase in demand for Anti-Fibrinolytic Drugs. The increasing healthcare expenditure by the government and private players in the region is also contributing to the growth of the market. Additionally, the presence of major pharmaceutical companies in the region is driving the development of new and advanced drugs in the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.